Showing 1 - 10 of 710
Persistent link: https://www.econbiz.de/10000024549
Persistent link: https://www.econbiz.de/10014002175
This book discusses the full economic benefits - and costs - of transport infrastructure and explores ways to make good estimates of the full impact of planned investments on regional and national economies. It argues for proper account to be taken of all relevant economic weaknesses -- those...
Persistent link: https://www.econbiz.de/10012441349
Persistent link: https://www.econbiz.de/10012443190
Cost-benefit analysis (CBA) is indispensable for making good decisions on what transport projects to fund. It essentially aims to figure out which projects offer the best value for money. However, the practical relevance of CBA does not always live up to its appeal in principle. One problem is...
Persistent link: https://www.econbiz.de/10012443543
Are breast cancer survival rates higher in the United States than in the United Kingdom and France? Are a patient's chances of dying within 30 days after admission to a hospital with a heart attack lower in Canada than in Korea? Are surgeons in some countries more likely to leave “foreign...
Persistent link: https://www.econbiz.de/10012442819
Share price indices are calculated from the prices of common shares of companies traded on national or foreign stock exchanges. They are usually determined by the stock exchange, using the closing daily values for the monthly data, and normally expressed as simple arithmetic averages of the...
Persistent link: https://www.econbiz.de/10013526100
In recent years the scope for near perfect price discrimination, particularly in the digital economy, appears to have grown. This raises a question over how those jurisdictions in which exploitative price discrimination is an offence will respond. In contrast, the risk of price discrimination...
Persistent link: https://www.econbiz.de/10015081831
This paper explores excessive prices at the intersection between competition law and regulated sectors such as pharma. It was prepared as a background note for the OECD Competition Committee roundtable on “Excessive pricing in pharmaceuticals”, which took place in November 2018.
Persistent link: https://www.econbiz.de/10015082018
Persistent link: https://www.econbiz.de/10000026953